Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Assets (2017 - 2025)

Serina Therapeutics (SER) has disclosed Non-Current Assets for 9 consecutive years, with $871000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 16.89% to $871000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, down 45.14% year-over-year, with the annual reading at $871000.0 for FY2025, 16.89% down from the prior year.
  • Non-Current Assets hit $871000.0 in Q4 2025 for Serina Therapeutics, down from $916000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $11.1 million in Q3 2023 to a low of $788000.0 in Q4 2022.
  • Historically, Non-Current Assets has averaged $2.6 million across 5 years, with a median of $981000.0 in 2021.
  • Biggest five-year swings in Non-Current Assets: surged 1248.23% in 2023 and later tumbled 83.61% in 2024.
  • Year by year, Non-Current Assets stood at $920000.0 in 2021, then dropped by 14.35% to $788000.0 in 2022, then skyrocketed by 71.19% to $1.3 million in 2023, then dropped by 22.31% to $1.0 million in 2024, then fell by 16.89% to $871000.0 in 2025.
  • Business Quant data shows Non-Current Assets for SER at $871000.0 in Q4 2025, $916000.0 in Q3 2025, and $950000.0 in Q2 2025.